More than 4000 breast, prostate or lung cancer patients have been recruited at 25 institutions. This represents 75% of target with recruitment ongoing.
Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors
The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy
Tim Ward, a member of REQUITE's patient advisory group (PAG), showed a REQUITE poster at the UK Radiation Oncology Conference (UKRO) in Liverpool on 6-8 June 2016. UKRO is a multi-disciplinary three day scientific conference organised on behalf of the British Institute of Radiology, the Society and College of Radiographer and the Institute of Physics and Engineering in Medicine.
We can look back on a productive Congress in Maastricht. The fourth Annual REQUITE meeting was held on Monday 11th July (afternoon) and Tuesday 12th July followed by the Radiogenomics consortium meeting on Wednesday 13th July.The work of the past year and the first research results were presented and analyzed and new actionpoints were made. New upcoming projects were also presented. There was plenty of opportunity for engaging discussions and to exchange knowledge.
The 4th Annual REQUITE Meeting and the 8th Annual Meeting of the Radiogenomics Consortium will take place from 11 - 13 July, 2016 in Maastricht, the Netherlands and is hosted by MAASTRO-Clinic.
Many of the researchers involved in the REQUITE project are also part of the Radiogenomics consortium. A good reason to combine both yearly meetings at one moment of the year in the same venue, giving the involved people the opportunity to attend both meetings.
This is one conference joining the activities of four scientific disciplines:
Medical Informatics (MIE2016), Medical Biometry, Bioinformatics, Epidemiology and Health Data Management.
It will serve as an important scientific forum for the exchange of new ideas and applications to strengthen health sciences on a national and international level. http://www.hec2016.eu/
The ASTRO Annual Meeting is the world's most important meeting for the radiation oncology community, with more than 11,000 people attending each year. Highlights include:
- The latest ground-breaking science presented at the Plenary and Clinical Trials Sessions.
- Special physics and biology oral abstract sessions.
- More than 1,700 paper posters and multiple ePoster sessions.
- A full program of education sessions, panels and workshops covering all disease sites and tracks.
- A full Exhibit Hall, guideline updates, special events and many networking opportunities.
The World Cancer Congress is run by the Union for International Cancer Control (UICC) and takes place every two years in a different country, always hosted by a UICC member organisation. The conference is aligned with UICC's purpose statement of uniting the cancer community, to reduce the global cancer burden, to promote greater equity and to integrate cancer into the world's health and development agenda.
The NCRI Cancer Conference showcases the latest basic, translational and clinical cancer research. It brings researchers together to share ideas and develop collaborations. The National Cancer Research Institute is a UK-wide partnership between research funders working together to make faster progress against cancer.